[{"id":"fa2b9899-956d-4a45-a9c3-8729c5d6b741","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856447","created_at":"2025-09-07T01:48:31.731Z","updated_at":"2025-09-07T01:48:31.731Z","phase":"Phase 1","brief_title":"The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","source_id_and_acronym":"NCT06856447","lead_sponsor":"toqa saad mohammed mohammed","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 05/20/2025","primary_completion_date":" 05/20/2025","study_txt":" Completion: 01/10/2026","study_completion_date":" 01/10/2026","last_update_posted":"2025-03-04"},{"id":"381bf29b-94cb-4456-94ac-4f2cac19d9f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06852014","created_at":"2025-03-03T09:58:31.668Z","updated_at":"2025-03-03T09:58:31.668Z","phase":"","brief_title":"Effects of Peptamen 1.6 in Malnourished Patients (or At Risk) with Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): a Mechanistic Study","source_id_and_acronym":"NCT06852014","lead_sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-28"},{"id":"247549cd-8895-4562-99d4-e47d7bf8dd69","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923104","created_at":"2021-01-18T03:34:22.610Z","updated_at":"2025-02-25T13:48:00.941Z","phase":"","brief_title":"An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin","source_id_and_acronym":"NCT00923104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • TNFA • IL1B • MMP1","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B • MMP1"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 04/23/2009","start_date":" 04/23/2009","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"48df85e5-b786-45f4-a391-eab53ca69d44","acronym":"AMPLIFY","url":"https://clinicaltrials.gov/study/NCT04000880","created_at":"2024-02-21T19:24:47.029Z","updated_at":"2025-02-25T13:48:43.597Z","phase":"","brief_title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","source_id_and_acronym":"NCT04000880 - AMPLIFY","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-21"},{"id":"6076406a-9463-43ad-ba76-13f9a5a2bd1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445288","created_at":"2021-01-18T05:59:39.581Z","updated_at":"2025-02-25T13:39:05.076Z","phase":"","brief_title":"Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","source_id_and_acronym":"NCT01445288","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • TNFA","pipe":"","alterations":" ","tags":["VEGFA • TNFA"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/05/2006","start_date":" 12/05/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"9a2be334-2a03-47f4-bac6-d53ac52c474b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05286801","created_at":"2022-03-18T11:54:26.510Z","updated_at":"2025-02-25T14:08:43.679Z","phase":"Phase 1/2","brief_title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","source_id_and_acronym":"NCT05286801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["TNFA • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"0b525e9d-4ff9-4d49-a886-decd1a174c57","acronym":"","url":"https://clinicaltrials.gov/study/NCT04643574","created_at":"2021-01-19T20:39:09.813Z","updated_at":"2025-02-25T14:40:41.852Z","phase":"Phase 1","brief_title":"NeoTIL in Advanced Solid Tumors","source_id_and_acronym":"NCT04643574","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" TNFA • IL2","pipe":"","alterations":" ","tags":["TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-14"},{"id":"86782c45-c567-43a8-9173-9539c1107862","acronym":"","url":"https://clinicaltrials.gov/study/NCT06825221","created_at":"2025-02-25T15:16:27.848Z","updated_at":"2025-02-25T15:16:27.848Z","phase":"","brief_title":"Effect of Immune Formula in Gastrointestinal Cancer Patients Undergoing Cancer Surgery","source_id_and_acronym":"NCT06825221","lead_sponsor":"Chulalongkorn University","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2025-02-13"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"f48f1b5b-016c-486a-b2f8-c14558815182","acronym":"","url":"https://clinicaltrials.gov/study/NCT03794349","created_at":"2023-11-21T16:15:50.470Z","updated_at":"2025-02-25T15:11:00.647Z","phase":"Phase 2","brief_title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT03794349","lead_sponsor":"Children's Oncology Group","biomarkers":" IFNG • IL6 • CD276 • TNFA","pipe":"","alterations":" ","tags":["IFNG • IL6 • CD276 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-13"},{"id":"c3f91db3-f89a-454a-9211-dc69a8dcc486","acronym":"EOSDOEOSQ","url":"https://clinicaltrials.gov/study/NCT06773143","created_at":"2025-02-25T15:37:59.408Z","updated_at":"2025-02-25T15:37:59.408Z","phase":"","brief_title":"Effect of Subanesthetic Dose of Esketamine on Sleep Quality","source_id_and_acronym":"NCT06773143 - EOSDOEOSQ","lead_sponsor":"Nanjing First Hospital, Nanjing Medical University","biomarkers":" IL6 • TNFA • BDNF","pipe":"","alterations":" ","tags":["IL6 • TNFA • BDNF"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 12/30/2024","start_date":" 12/30/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-10"},{"id":"9eaff877-3912-4232-9211-c73f401a599e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06741540","created_at":"2025-02-25T16:41:58.840Z","updated_at":"2025-02-25T16:41:58.840Z","phase":"","brief_title":"Effects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression","source_id_and_acronym":"NCT06741540","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER • PGR • IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-07"},{"id":"8558f5f4-3c34-4ca5-977c-ce483a267ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06811220","created_at":"2025-02-25T16:50:25.446Z","updated_at":"2025-02-25T16:50:25.446Z","phase":"Phase 3","brief_title":"The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients","source_id_and_acronym":"NCT06811220","lead_sponsor":"Alexandria University","biomarkers":" TNFA • IL1B","pipe":"","alterations":" ","tags":["TNFA • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/27/2025","start_date":" 01/27/2025","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-06"},{"id":"c18480ea-e56b-4074-80ac-afaf290dce63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556045","created_at":"2021-01-18T21:46:44.852Z","updated_at":"2025-02-25T16:53:16.785Z","phase":"","brief_title":"Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer","source_id_and_acronym":"NCT04556045","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-04"},{"id":"7cf69f5a-aff7-4427-8529-8794fca88989","acronym":"","url":"https://clinicaltrials.gov/study/NCT05268991","created_at":"2022-03-07T18:54:01.348Z","updated_at":"2025-02-25T17:37:39.901Z","phase":"","brief_title":"Aging and Frailty Study","source_id_and_acronym":"NCT05268991","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 01/07/2025","primary_completion_date":" 01/07/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-29"},{"id":"d7cdffc4-f22c-4043-a30f-9144f9def49d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04720209","created_at":"2021-01-22T12:54:16.002Z","updated_at":"2025-02-25T17:36:58.808Z","phase":"","brief_title":"Taking AIM at Breast Cancer","source_id_and_acronym":"NCT04720209","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PGR • IL6 • TNFA","pipe":"","alterations":" ","tags":["PGR • IL6 • TNFA"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2026","study_completion_date":" 06/15/2026","last_update_posted":"2025-01-29"},{"id":"2e87885c-4e7c-4eee-af7f-c60a1af4ea15","acronym":"SPIRAL","url":"https://clinicaltrials.gov/study/NCT06785974","created_at":"2025-02-25T19:12:33.814Z","updated_at":"2025-02-25T19:12:33.814Z","phase":"Phase 4","brief_title":"Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis","source_id_and_acronym":"NCT06785974 - SPIRAL","lead_sponsor":"Erasmus Medical Center","biomarkers":" IL6 • TNFA • IL10 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-01-22"},{"id":"a78706c6-c75a-4948-a72e-5e293212da18","acronym":"","url":"https://clinicaltrials.gov/study/NCT03626220","created_at":"2025-02-25T19:10:33.948Z","updated_at":"2025-02-25T19:10:33.948Z","phase":"","brief_title":"Acupuncture on Chemotherapy-induced Peripheral Neuropathy","source_id_and_acronym":"NCT03626220","lead_sponsor":"China Medical University Hospital","biomarkers":" TNFA • IL10","pipe":"","alterations":" ","tags":["TNFA • IL10"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 10/10/2020","study_completion_date":" 10/10/2020","last_update_posted":"2025-01-20"},{"id":"067f213e-03a5-45b6-8ae7-e5474fb8a9c9","acronym":"C-906289-002","url":"https://clinicaltrials.gov/study/NCT05308264","created_at":"2025-02-25T20:13:27.067Z","updated_at":"2025-02-25T20:13:27.067Z","phase":"Phase 1/2","brief_title":"Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)","source_id_and_acronym":"NCT05308264 - C-906289-002","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" TNFA • CRP","pipe":" | ","alterations":" Chr del(5q)","tags":["TNFA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R289"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/12/2022","start_date":" 09/12/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-16"},{"id":"08da958b-deab-46fd-9448-9e7d0dc1d817","acronym":"KEYNOTE B84","url":"https://clinicaltrials.gov/study/NCT04815720","created_at":"2021-03-25T11:52:15.829Z","updated_at":"2025-02-25T16:11:18.429Z","phase":"Phase 1/2","brief_title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04815720 - KEYNOTE B84","lead_sponsor":"Vaccinex Inc.","biomarkers":" PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-01-08"},{"id":"29969cfe-2b37-4195-9895-8e10c1f2fc4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06482905","created_at":"2025-02-26T07:12:20.689Z","updated_at":"2025-02-26T07:12:20.689Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","source_id_and_acronym":"NCT06482905","lead_sponsor":"Tcelltech Inc.","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/04/2024","start_date":" 09/04/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-08"},{"id":"e083e3f6-9297-475c-8844-e43c062a3d0a","acronym":"DAANCE","url":"https://clinicaltrials.gov/study/NCT06749210","created_at":"2025-02-26T07:40:40.489Z","updated_at":"2025-02-26T07:40:40.489Z","phase":"Phase 2","brief_title":"DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY","source_id_and_acronym":"NCT06749210 - DAANCE","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • IL10 • BDNF • GFAP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • BDNF • GFAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-01-06"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"}]